Short answers from the study record
What questions come up about BPC-157 TB-500?
You’ll find direct answers about both substances. Each one says whether the finding came from animals, people, or no study at all.
What goes into the Wolverine mix?
Where does the name Wolverine come from?
Sellers came up with Wolverine as a label for BPC-157 and TB-500 offered to you as a pair. Each is a peptide, a short chain made of amino acids, the small building blocks of protein; the mix lacks approval [1][3].
What are BPC-157 and TB-500 made from?
BPC-157 is a 15-amino-acid string that researchers first came across in work on a stomach protein. TB-500 is a lab-made protein part copied from Thymosin Beta-4 [1][3].
A seller may offer them to you together because each might affect healing by different means. A combined study hasn’t checked that idea for you.
What is the difference between BPC-157 and TB-500?
BPC-157’s 15-amino-acid chain has ties to tissue care and new blood vessels. TB-500 has a 7-amino-acid chain from Thymosin Beta-4 and has ties to cell movement [3][4].
The first weighs about 1419 daltons and the second about 889 daltons, a dalton being the unit for weighing tiny molecules. So the first is much the heavier, one more sign they're separate substances.
Why do sellers combine BPC-157 and TB-500 in the Wolverine stack?
The idea joins BPC-157’s blood-vessel findings with TB-500’s cell-movement findings [2][3][4]. For your choice, it comes from separate studies, not a fair test of the mix.
How did each part affect cells in early studies?
How might TB-500 change the movement of cells?
TB-500 is a short protein part copied from Thymosin Beta-4. X-ray pictures caught the parent protein holding actin, the material of a cell's crawling strands, in a 1:1 pair [3]. That might alter a cell's travel, yet it can't forecast your healing.
Researchers also produced a brief section taken from Thymosin Beta-4 so drug tests could spot TB-500 [9]. That work didn’t test whether the protein part helped your injury.
How did BPC-157 and TB-500 act differently?
BPC-157 set off signals that got tiny blood vessels growing. TB-500's parent protein holds on to actin, so the two may affect repair in different ways inside your body [2][3].
Can both substances help new blood vessels form?
Animal and dish studies linked both to new blood vessels. BPC-157 started growth steps inside vessel cells [2], while Thymosin Beta-4 helped those cells move [4].
That shared BPC-157 and TB-500 finding helps explain why sellers pair them. It still doesn’t prove the mix would help, or be safe, for you.
What have the injury studies found?
Which injuries were studied, and who was tested?
Separate animal studies covered wounds and repair of tendons, ligaments, muscles, and blood vessels [1][4][6]. No human trial has shown that the mix works for you.
What did rat studies find about the BPC-157 TB-500 blend and tendons?
BPC-157 helped a rat Achilles tendon that researchers cut [1] and a cut rat knee ligament [6]. The pair lacks a fair test, so you can’t expect the rat result in your tendon.
What did BPC-157 and TB-500 studies find in torn muscles?
In rats, researchers tested BPC-157 after cutting the big front thigh muscle loose from bone [13]. Separate Thymosin Beta-4 work found repair cells moving toward hurt tissue [4].
The mix hasn’t been proved for a human muscle tear. Your exam and a scan may tell you more about your own injury.
Has the BPC-157 TB-500 blend healed a wound in people?
One-substance animal work found wound changes, including new skin and blood vessels with Thymosin Beta-4 [4]. No study in people or study of the mix has proved a benefit for your wound.
When might BPC-157 and TB-500 change an injury?
No human study gives a time for the mix. Separate animal studies found changes over days to weeks [1][6], but that can’t set your healing time or your next step.
Has any study shown BPC-157 and TB-500 work better together?
Published work checked by other scientists hasn’t shown that the pair helps you more. A 2025 review of BPC-157 for bone and joint doctors said nothing about TB-500 or the pair [10].
Is there a fair human study of the BPC-157 + TB-500 mix?
There aren’t controlled human trials of the blend. The small amount of human work used single parts, and TB-500 claims come from the full Thymosin Beta-4 protein rather than its much shorter piece [4][9][10].
I’d ask to see the exact study behind any claim made at a visit. For BPC-157 and TB-500, you’ll want to know who was tested and what changed.
What do dose and mixing questions mean?
What do sellers mean by a BPC-157 and TB-500 “cycle”?
A cycle is a schedule with a period of use followed by a stop or change, but published work gives you no tested cycle for the mix. Vials marked 10 milligrams + 10 milligrams and online plans that start with more don’t come from controlled human trials.
One rat study found that more Thymosin Beta-4 wasn’t better. That finding can’t create a human plan.
Has research proved a weekly amount for BPC-157 and TB-500?
Research hasn’t proved a weekly amount for you. BPC-157 at about 10 micrograms for every kilogram of animal weight [1] and the broad Thymosin Beta-4 amounts based on weight came from animals, not people.
What do studies say about how long BPC-157 and TB-500 remain in you?
Animal work put BPC-157’s half-life, the time for half to leave the body, under 30 minutes. Human studies don’t give that time for either substance or the mix in your body.
No exact time is known for the short TB-500 form. Work on the full protein can’t fill that gap.
What does adding sterile water to the dry blend do?
Adding sterile water turns dry powder into a liquid. The label can’t prove to you what’s inside or the split between BPC-157 and TB-500 in material sold outside firm drug rules [4][9].
There’s also doubt because most claims use studies of the full protein, rather than the shorter form sold in a vial. These facts aren’t mixing directions.
Do studies give any sound timing for the shots?
Published work offers you no sound shot schedule for BPC-157 and TB-500. Plans that start with more and later use less have no fair human test behind them.
The timing remains unknown. A common online plan isn’t a tested plan.
What safety worries are known?
Which unwanted effects are known for BPC-157 and TB-500?
The blend’s safety hasn’t been proved. Thymosin Beta-4 can move cells and help tiny vessels form, which might also aid a tumor in your body [4].
Long-term BPC-157 safety is unknown for you and everyone else. A 2025 review found no sound patient safety data [10].
What is the tumor worry around TB-500?
Thymosin Beta-4 has been tied to tumors spreading and to vessel growth [4]. Lab work gives a reason for concern, but it doesn’t prove the short form causes cancer in your body.
What do FDA and sports rules say?
What do FDA approval and sports rules mean if you use BPC-157 and TB-500?
Both substances lack FDA approval for use in people [14]. In sport, WADA, the World Anti-Doping Agency, forbids BPC-157 as a drug never approved anywhere, and bans TB-500 under rules for substances that can change cell growth.
Does Wolverine have FDA approval?
No use of the mix has FDA approval, and neither BPC-157 nor the small TB-500 part copied from Thymosin Beta-4 is approved. FDA listed both in Category 2, its serious-safety-worry group for pharmacy ingredients, in its September 29, 2023 update [14].
Later on, both pharmacy-use requests were pulled back. See the full FDA pharmacy record for Wolverine to learn what the withdrawal means for you and your pharmacy.
What still blocks a pharmacy from making BPC-157 for you?
FDA’s page current through April 22, 2026 shows BPC-157 outside Category 2 because the request was withdrawn [14]. FDA’s page keeps the safety concerns and leaves your pharmacy guessing what the change means.
Advisers discussed the issue at a meeting in July 2026. FDA hasn’t made their votes public [16].
What do FDA’s dated pages say about Wolverine?
FDA put BPC-157 and the small TB-500 part copied from Thymosin Beta-4 in Category 2 on September 29, 2023. Its page dated April 22, 2026 lists each request as withdrawn and outside Category 2 [14].
Before the July 23-24, 2026 meeting about the small part copied from Thymosin Beta-4, FDA's own staff advised the panel not to put either one on the list of allowed pharmacy ingredients. As of September 17, 2026, FDA hadn’t posted the adviser votes [16].